OMEICOS Therapeutics GmbH - Ophthalmology


OMEICOS Therapeutics, through its US subsidiary OMEICOS Ophthalmics, is dedicated to providing an alternative, non-invasive treatment option for patients by leveraging its proprietary technology and successes from preclinical studies to suppress neovascularization in the eye. OMEICOS Ophthalmics, established in Boston, MA, in August 2017, will focus on a clinical development program for ophthalmological indications.


Macular Edema Diseases

Macular edema is the swelling and thickening of the macula lutea, a small area at the center of the eye’s retina that is normally responsible for sharp vision. Fluid build-up causes the macula to swell and thicken, thereby distorting vision. Macular edema also occurs due to abnormal formation of very small and leaky blood vessels in the retina, also known as choroidal neovascularization (CNV). Macular edema and CNV contribute to loss of vision in several ocular diseases with a chronic inflammatory mechanism, including wet age-related macular degeneration (AMD) and diabetic retinopathy. AMD is the leading cause of severe vision loss in individuals over 65 years of age.   

The current clinical treatment option for wet AMD is anti-VEGF therapy – an intravitreal (into the eye) injection of an ‘anti-VEGF’-drug, which helps to prevent the formation of weak, leaky blood vessels. Although effective, patients show high recurrence of wet AMD after multiple treatments. 

A better treatment option for wet AMD is a top unmet medical need to i) reduce the burden of repeated, frequent injections into the eye, and ii) offer therapies with more convenient routes of administration. 



In 2014, approximately 13% of the population of the G7 countries, aged 40 or older, were living with early AMD, and around 1% with late AMD. 

The prevalence of AMD increases with age. The total prevalent cases of AMD across the G7 countries will see a 14% growth over a 2014-2024 forecast. 

In 2014, the total G7 market for AMD-drug therapies was USD 4,59 bn and was dominated by VEGF-inhibitors accounting for 99% market share. Decision Resources estimates the market to grow to USD 8.25 bn by 2024.